Multiple-Dose, Dose-Escalation Study to Evaluate the Safety/Tolerability and Pharmacokinetics of FP-045

Healthy Volunteers Clinical Trial

Official title:

A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety/Tolerability and Pharmacokinetics of FP-045 Administered Orally to Normal, Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03686930
• Other study ID #: FP045C-17-001
• Status: Completed
• Phase: Phase 1
• Start date: February 22, 2018
• Est. completion date: August 10, 2018

Study information

• Verified date: April 2022
• Source: Foresee Pharmaceuticals Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase I, single-center, randomized, double-blind, placebo-controlled, multiple ascending dose (MAD), study to evaluate the safety/tolerability and pharmacokinetics (PK) of FP-045 administered to normal health volunteers (NHVs). 3 cohorts of NHVs will be enrolled. Subjects in each cohort will be randomized to orally receive either FP-045 (6 subjects) or placebo (2 subjects). Subjects will receive 7 daily doses of study drug.

Subjects will be screened for study eligibility within 21 days before Day 1 and will have been admitted to the CRU on Day -1 to confirm eligibility and to undergo baseline assessments. Subjects will remain in the CRU for observation until completion of all assessments on Day 10. Subjects will return to the CRU on Day 11 for an additional PK sample, and again for an end of study (EOS) Visit on Day 14 (±2 days) for safety evaluations and collection of PK samples.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: August 10, 2018
• Est. primary completion date: May 27, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Male or female NHV, age 18 to 55 years, inclusive (at the time of informed consent).

2. Females must be either postmenopausal for =1 year (or with FSH = 40 mIU/mL if postmenopausal for < 1 year) or surgically sterile (having undergone bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) for at least 6 months.

3. Males with female partners of childbearing potential must agree to use barrier contraceptive (i.e., condom) and their female partners must use a highly effective method of contraception from Screening through 90 days after the last dose of study drug. Males must also refrain from sperm donations during this time period.

Males who are abstinent will not be required to use a contraceptive method unless they become sexually active.

4. The subject is, in the opinion of the Investigator, generally healthy based on assessment of medical history, physical examination, vital signs, electrocardiogram (ECG), and the results of the hematology, clinical chemistry, urinalysis, serology, and other laboratory tests.

5. Baseline laboratory test values within reference ranges based on the blood and urine samples taken at Screening and on Day -1 (before administration of the initial study drug). Out of normal ranges values may be accepted by the Investigator, if not clinically significant.

6. Nonsmoker and/or ex-smoker who has discontinued smoking and/or use of nicotine containing products for at least 6 months prior to the first dose of study drug

7. Body mass index between 18 and 30 kg/m2, inclusive

8. Written informed consent obtained Ability to communicate well with the Investigator, in the local language, and to understand and comply with the requirements of the study.

Exclusion Criteria:

1. History or presence of any clinically significant neurological, metabolic, gastrointestinal, endocrinological (in particular diabetes or pre-diabetes), cardiovascular, hematological, hepatic, immunological, renal, respiratory, chronic infections, psychiatric, or genitourinary abnormalities or diseases. Note: NHVs with a history of uncomplicated kidney stones or asthma may be enrolled in the study at the discretion of the Investigator.

2. History of malignant neoplastic disease, with the following exceptions:

1. Adequately treated non-melanomatous skin carcinoma

2. Female with a history of benign cervical carcinoma neoplasia if compliant with surveillance and treatment as recommended by her physician

3. Mentally or legally incapacitated, has significant emotional problems at Screening or expected during the conduct of the study, or has a history of a clinically significant psychiatric disorder within the last 5 years. Note: NHVs who have had situational depression may be enrolled in the study at the discretion of the Investigator.

4. The subject has a history of severe drug allergy or hypersensitivity or food allergy, including anaphylaxis.

5. The subject has had surgery or trauma with significant blood loss within the last 3 months prior to the first dose of study drug.

6. The subject has donated blood more than 1 unit (500 mL) with 4 weeks prior to the first dose of study drug.

7. Fever (body temperature >38°C) or symptomatic viral or bacterial infection within 2 weeks prior to Screening

8. Blood pressure >140/90 mm Hg or heart rate >100 beats per minute at Screening or at Day -1. Vitals may be repeated up to 2 times for the purpose of eligibility.

9. Clinically significant laboratory abnormalities including:

1. Impaired renal function (serum creatinine levels >ULN) at Screening; estimated creatinine clearance (CrCl) of <80 mL/min

2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) laboratory values >1.2 × upper normal limits

10. Clinically significant abnormality on ECG performed at Screening or prior to administration of the initial dose of study drug. (Screening ECG conduction intervals must be 10. Clinically significant abnormality on ECG performed at Screening or prior to administration of the initial dose of study drug. (Screening ECG conduction intervals must be within gender specific normal ranges [QT interval corrected for heart rate [QTc] males =450 msec and females =470 msec].)

11. Positive test for hepatitis C antibody, hepatitis B surface antigen, or human immunodeficiency virus antibody at Screening

12. Positive screen for drugs with a high potential for abuse (amphetamine, cannabinoid, cocaine, morphine, and phencyclidine) at Screening and Study Day -1.

13. Consumed food or drink containing grapefruit juice within 72 hours before start of dosing or expected to do so through EOS/ET

14. Consumed alcohol within 72 hours before start of dosing through EOS/ET.

15. Received any previous FP-045 or has taken any investigational product within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug.

16. Female who is breastfeeding or has a positive pregnancy test

17. Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's return for the scheduled EOS Visit

18. The subject has taken prescription medications within 2 weeks (or within 5 half-lives, whichever is longer) or nonprescription medication, herbal remedies, vitamins or minerals within 1 week prior to the administration of the initial dose of study drug and continuing throughout the study until the final study visit. Note: There may be certain medications that are permitted at the discretion of the Investigator and Sponsor (including paracetamol/ acetaminophen, which may be used for minor ailments during the course of the study without prior consultation with the Sponsor's Medical Monitor).

19. The subject exercises extensively (e.g. marathon, triathlon or other similar high energetic sports). In general, subjects should refrain from sporting for at least 4 days before participation in the study until the EOS/ET visit.

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Drug:
• Cohort 1 - FP-045 oral solution
FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
• Cohort 2 - FP-045 oral solution
FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
• Cohort 3 - FP-045 oral solution
FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
• Placebo (for FP-045 oral solution)
Participants (cohorts 1-3) will receive FP-045 oral solution matching placebo.

Locations

Country	Name	City	State
Australia	Nucleus Networks	Melbourne

Sponsors (1)

Lead Sponsor	Collaborator
Foresee Pharmaceuticals Co., Ltd.

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in baseline measures for vital sign parameters [safety/tolerability]	Outcome Measures units of measure include weight in kilograms.	14 days ± 2 days
Primary	Change in baseline measures for ECG parameters [safety/tolerability]	T wave	14 days ± 2 days
Primary	Change in baseline measures for clinical laboratory test [safety/tolerability]	Number of Participants with Abnormal Laboratory Values. Blood will be drawn to measure the chemistry of the blood prior to and after dosing.	14 days ± 2 days
Primary	Number of participants with treatment-emergent ECG abnormalities [safety/tolerability].		14 days ± 2 days
Primary	Number of participants with treatment-emergent AEs [safety/tolerability].		14 days ± 2 days
Primary	Number of participants with treatment-emergent AEs leading to premature discontinuation of study drug [safety/tolerability].		14 days ± 2 days
Primary	Number of participants with treatment-emergent SAEs [safety/tolerability].		14 days ± 2 days
Primary	Change in baseline measures for vital sign parameters [safety/tolerability]	Outcome Measures units of measure include height in meters.	14 days ± 2 days
Primary	Change in baseline measures for vital sign parameters [safety/tolerability]	Outcome Measures units of measure include blood pressure both systolic and diastolic will be measured.	14 days ± 2 days
Secondary	Pharmacokinetic (PK) profile (Cmax) following multiple, escalating oral doses of FP-045.	Cmax (maximum plasma concentration) -first and last doses (Day 1 and Day 7) of FP-045 will be measured.	14 days ± 2 days
Secondary	Pharmacokinetic (PK) profile (Tmax) following multiple, escalating oral doses of FP-045.	Tmax (time to maximum plasma concentration) -first and last doses (Day 1 and Day 7) of FP-045 will be measured.	14 days ± 2 days
Secondary	Pharmacokinetic (PK) profile (AUC0-24) following multiple, escalating oral doses of FP-045.	AUC0-24 (area under the curve from time 0 to 24 hours postdose) - first dose (Day 1) of FP-045 will be measured.	14 days ± 2 days
Secondary	Pharmacokinetic (PK) profile (Cavg) following multiple, escalating oral doses of FP-045.	Cavg (average plasma concentration over the dosing interval) = AUC0-24/t, where t is the dosing interval - last dose (Day 7) of FP-045 will be measured.	14 days ± 2 days
Secondary	Pharmacokinetic (PK) profile (accumulation ratio of AUC0-24) following multiple, escalating oral doses of FP-045.	Accumulation ratio of AUC0-24 (Day 7)/AUC0-24 (Day 1) of FP-045 will be measured.	14 days ± 2 days
Secondary	Pharmacokinetic (PK) profile (AUC[0-24]) following multiple, escalating oral doses of FP-045.	AUC[0-24](area under the curve over the dosing interval) - Day 7 of FP-045 will be measured.	14 days ± 2 days
Secondary	Other pharmacokinetic (PK) profiles measured include t1/2 (terminal half-life) following multiple, escalating oral doses of FP-045.		14 days ± 2 days
Secondary	Other pharmacokinetic (PK) profiles measured include CL/F (apparent clearance) following multiple, escalating oral doses of FP-045.		14 days ± 2 days
Secondary	Other pharmacokinetic (PK) profiles measured include Vz/F (apparent volume of distribution) following multiple, escalating oral doses of FP-045.		14 days ± 2 days
Secondary	Other pharmacokinetic (PK) profiles measured include elimination rate constant following multiple, escalating oral doses of FP-045.		14 days ± 2 days